Log in

Venus Remedies

VENUSREM· NSE· Healthcare
₹1,525.30
−₹35.40 (−2.27%) · 1Das of 17 Nov 2026, 23:30 IST

Venus Remedies (VENUSREM) last traded at ₹1,525.30 on NSE as of 17 Nov 2026, 23:30 IST, down 2.27% (−₹35.40) on the day. Market cap ₹2,039 crore, trailing P/E 19.8×, P/B 3.1×, EPS ₹76.89. Sector: Healthcare.

Day range₹1,505.10 – ₹1,595.00
52-week range—
Volume19,456
Market cap₹2,039 crore
P/E · P/B19.8× · 3.1×trailing
EPS₹76.89
Returns1W+5.20%1M—3M—6M—YTD—1Y—3Y—5Y—

Fundamentals

Revenue growth· latest year+18.79%
Net margin13.4%
ROE / ROA— / 12.0%
Debt-to-equity—
P/E · P/B· trailing19.8× · 3.1×
EPS₹76.89
Revenue / net income₹770 crore / ₹103 crore
Last reported year ends 31 Mar 2026

Technicals

RSI (14)—
20-day average· ——
50-day average· ——
200-day average· ——
ATR (14)—
20-session change—
Volatility· 30 sessions, annualised—
From completed sessions; the RSI alone steps with the live price.

Sector today

Healthcare
Move today+0.02%
Breadth40% of stocks up
RotationLagging
Against the NIFTY 50 · breadth is the share of the sector's stocks up today

Latest news

All VENUSREM news

No publisher article about Venus Remedies in the last 7 days.

Upcoming events

Event calendar

No upcoming company event is listed for Venus Remedies.

Frequently asked

What is the Venus Remedies share price today?

Venus Remedies (VENUSREM) last traded at ₹1,525.30 on NSE as of 17 Nov 2026, 23:30 IST, down 2.27% (−₹35.40) on the day.

What is the market capitalisation of Venus Remedies?

₹2,039 crore at the last price (NSE's issued shares × price).

What is the P/E ratio of Venus Remedies?

Trailing P/E 19.8× on EPS ₹76.89, from the annual statement for the year ended 31 Mar 2026.

Which sector is Venus Remedies in, and how is the sector doing today?

Healthcare. The sector is up 0.02% today, with 40% of its stocks up (Lagging against the NIFTY 50).

What is the next scheduled event for Venus Remedies?

No upcoming company event is listed for Venus Remedies.

Data as of 17 Nov 2026, 23:30 IST · Research, not investment advice.